Intra-patient evolution of tumor microenvironment in the pathogenesis of treatment-naïve metastatic melanoma patients

References

• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127–137. doi:10.1200/JCO.21.02229.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Ascierto PA, Schadendorf D, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials. Eur J Cancer. 2020;125:114–120. doi:10.1016/j.ejca.2019.10.033.
   PubMed Web of Science ®Google Scholar
• Sahu A, Kose K, Kraehenbuehl L, et al. In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response. Nat Commun. 2022;13(1):5312. doi:10.1038/s41467-022-32738-7.
   PubMed Web of Science ®Google Scholar
• Attrill GH, Lee H, Tasker AT, et al. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome. Front Immunol. 2022;13:979993. doi:10.3389/fimmu.2022.979993.
   PubMed Web of Science ®Google Scholar
• Garg M, Couturier D-L, Nsengimana J, et al. Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nat Commun. 2021;12(1):1137. doi:10.1038/s41467-021-21207-2.
   PubMed Web of Science ®Google Scholar
• Grzywa TM, Paskal W, Włodarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol. 2017;10(6):956–975. doi:10.1016/j.tranon.2017.09.007.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. doi:10.1038/nature12213.
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–2147. doi:10.1056/NEJMoa050092.
   PubMed Web of Science ®Google Scholar
• Ito T, Tanaka Y, Murata M, et al. BRAF heterogeneity in melanoma. Curr Treat Options Oncol. 2021;22(3):20. doi:10.1007/s11864-021-00818-3.
   PubMedGoogle Scholar
• Pellegrini C, Cardelli L, Padova M, et al. Intra-patient heterogeneity of BRAF and NRAS molecular alterations in primary melanoma and metastases. Acta Derm Venereol. 2020;100(1):adv00040. doi:10.2340/00015555-3382.
   Google Scholar
• Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: a meta-analysis. Eur J Cancer. 2017;81:106–115. doi:10.1016/j.ejca.2017.05.015.
   PubMed Web of Science ®Google Scholar
• Wang M, Zadeh S, Pizzolla A, et al. Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. J Immunother Cancer. 2022;10:e004095. doi:10.1136/jitc-2021-004095.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi:10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar
• Xiong D, Wang Y, You M. A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response. Nat Commun. 2020;11(1):5084. doi:10.1038/s41467-020-18546-x.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy. Science. 2018;362:eaar3593. doi:10.1126/science.aar3593.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1.
   PubMed Web of Science ®Google Scholar
• Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765–779. doi:10.1002/eji.201646875.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Linnskog R, Jönsson G, Axelsson L, et al. Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression. Mol Oncol. 2014;8(8):1365–1378. doi:10.1016/j.molonc.2014.05.008.
   PubMed Web of Science ®Google Scholar
• Fu T, Liu J-X, Xie J, et al. LAMC2 as a prognostic biomarker in human cancer: a systematic review and meta-analysis. BMJ Open. 2022;12(11):e063682. doi:10.1136/bmjopen-2022-063682.
   PubMed Web of Science ®Google Scholar
• Wagner NB, Weide B, Gries M, et al. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J Immunother Cancer. 2019;7:343.
   PubMed Web of Science ®Google Scholar
• Berciano-Guerrero M-A, Lavado-Valenzuela R, Moya A, et al. Genes involved in immune reinduction may constitute biomarkers of response for metastatic melanoma patients treated with targeted therapy. Biomedicines. 2022;10:284. doi:10.3390/biomedicines10020284.
   PubMed Web of Science ®Google Scholar
• Chiriboga L, Meehan S, Osman I, et al. Endothelin-1 in the tumor microenvironment correlates with melanoma invasion. Melanoma Res. 2016;26(3):236–244. doi:10.1097/CMR.0000000000000235.
   PubMed Web of Science ®Google Scholar
• Smith MP, Rowling EJ, Miskolczi Z, et al. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med. 2017;9(8):1011–1029. doi:10.15252/emmm.201607156.
   PubMed Web of Science ®Google Scholar
• Xie R, Li B, Jia L, et al. Identification of core genes and pathways in melanoma metastasis via bioinformatics analysis. Int J Mol Sci. 2022;23:794. doi:10.3390/ijms23020794.
   PubMed Web of Science ®Google Scholar
• Yan J, Wu X, Yu J, et al. Prognostic role of tumor mutation burden combined With immune infiltrates in skin cutaneous melanoma based on multi-omics analysis. Front Oncol. 2020;10:570654. doi:10.3389/fonc.2020.570654.
   PubMed Web of Science ®Google Scholar
• Giuntini G, Coppola F, Falsini A, et al. Role of the hedgehog pathway and CAXII in controlling melanoma cell migration and invasion in hypoxia. Cancers. 2022;14:4776. doi:10.3390/cancers14194776.
   PubMed Web of Science ®Google Scholar
• Ma Z, Lian J, Yang M, et al. Overexpression of arginase-1 is an indicator of poor prognosis in patients with colorectal cancer. Pathol Res Pract. 2019;215(6):152383. doi:10.1016/j.prp.2019.03.012.
   PubMed Web of Science ®Google Scholar
• Tian C, Öhlund D, Rickelt S, et al. Cancer cell–derived matrisome proteins promote metastasis in pancreatic ductal adenocarcinoma. Cancer Res. 2020;80(7):1461–1474. doi:10.1158/0008-5472.CAN-19-2578.
   PubMed Web of Science ®Google Scholar
• Xue X, Liu Y, Chen X, et al. Pan-cancer analysis identifies NT5E as a novel prognostic biomarker on cancer-associated fibroblasts associated with unique tumor microenvironment. Front Pharmacol. 2022;13:1064032. doi:10.3389/fphar.2022.1064032.
   PubMed Web of Science ®Google Scholar
• Vizkeleti L, Kiss T, Koroknai V, et al. Altered integrin expression patterns shown by microarray in human cutaneous melanoma. Melanoma Res. 2017;27(3):180–188. doi:10.1097/CMR.0000000000000322.
   PubMed Web of Science ®Google Scholar
• Nurzat Y, Su W, Min P, et al. Identification of therapeutic targets and prognostic biomarkers Among integrin subunits in the skin cutaneous melanoma microenvironment. Front Oncol. 2021;11:751875. doi:10.3389/fonc.2021.751875.
   PubMed Web of Science ®Google Scholar
• Frangieh CJ, Melms JC, Thakore PI, et al. Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021;53(3):332–341. doi:10.1038/s41588-021-00779-1.
   PubMed Web of Science ®Google Scholar
• Pich C, Sarrabayrouse G, Teiti I, et al. Melanoma-expressed CD70 is involved in invasion and metastasis. Br J Cancer. 2016;114(1):63–70. doi:10.1038/bjc.2015.412.
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27(2):256–263. doi:10.1038/s41591-020-01211-7.
   PubMed Web of Science ®Google Scholar
• Patel SP, Othus M, Chen Y, et al. Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813–823. doi:10.1056/NEJMoa2211437.
   PubMed Web of Science ®Google Scholar
• Liu D, Lin J-R, Robitschek EJ, et al. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021;27(6):985–992. doi:10.1038/s41591-021-01331-8.
   PubMed Web of Science ®Google Scholar
• Cerezo-Wallis D, Contreras-Alcalde M, Troulé K, et al. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat Med. 2020;26(12):1865–1877. doi:10.1038/s41591-020-1073-3.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wu X. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. Int Immunopharmacol. 2017;46:210–219. doi:10.1016/j.intimp.2017.03.015.
   PubMed Web of Science ®Google Scholar
• Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195–1204. doi:10.1001/jamaoncol.2019.1549.
   PubMed Web of Science ®Google Scholar